Carmat SA (EPA: ALCAR)

Market Cap	48.15M
Revenue (ttm)	6.93M
Net Income (ttm)	-53.35M
Shares Out	44.50M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,836
Average Volume	220,814
Open	1.072
Previous Close	1.070
Day's Range	1.072 - 1.096
52-Week Range	0.960 - 4.640
Beta	1.40
RSI	48.55
Earnings Date	Dec 23, 2024

About Carmat

Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 182
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCAR

Financial Performance

In 2023, Carmat's revenue was 3.84 million, an increase of 704.40% compared to the previous year's 477,000. Losses were -53.87 million, 0.35% more than in 2022.